IL1B and metabolic dysfunction-associated steatotic liver disease: As inflammation in the liver is believed to be the compelling feature in NAFLD development, the inhibitory effect of compound C on proinflammatory mediators (i.e., IL-1β and IL-18) encouraged us to further investigate the underlying mechanisms.